

FRAILTY, OSTEOPOROSIS AND HIP FRACTURE: CAUSES, CONSEQUENCES AND THERAPEUTIC PERSPECTIVES

Y. ROLLAND¹, G. ABELLAN VAN KAN¹, A. BENETOS², H. BLAIN³, M. BONNEFOY⁴,
P. CHASSAGNE⁵, C. JEANDEL³, M. LAROCHE⁶, F. NOURHASHEMI¹, P. ORCEL⁷, F. PIETTE⁸,
C. RIBOT⁹, P. RITZ¹⁰, C. ROUX¹¹, J. TAILLANDIER¹², F. TREMOLLIERES⁹,
G. WERYHA¹³, B. VELLAS¹

1. Inserm U558, F-31073; Université de Toulouse III, F-31073 Toulouse, Gerontopôle de Toulouse, F-31059; 2. Centre de Gériatrie, CHU de Nancy, 1 INSERM Unité U684, Université de Nancy ; 3. Pôle de Gérontologie, Centre de Prévention et de Traitement des Maladies du Vieillessement, CHU Montpellier, 39, avenue Charles Flahault, 34295 Montpellier Cedex 5 ; 4. Service de Médecine Gériatrique, CHU Lyon-Sud ; 5. Service Médecine Interne Gériatrique, CHU Hôpital de Bois-Guillaume – 76031 Rouen Cedex ; 6. Service de Rhumatologie, CHU Rangueil, 1, avenue J. Poulhès, 31043 Toulouse cedex ; 7. C.H.U. Lariboisière Service de Rhumatologie 2 rue Ambroise Paré 75475 Paris ; 8. Hôpital Ch. Foix (Ivry), APHP, Université PM Curie ; 9. Centre de Ménopause, Hôpital Paule de Viguier, CHU Toulouse, 330 avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse cedex 9, Inserm U858-I2MR, CHU Rangueil, BP84225, 31432 Toulouse cedex 4 ; 10. Service de Médecine, CHU, 49033 Angers cedex 1 ; 11. Hôpital Cochin 27, rue du Fg St Jacques 75014 Paris ; 12. Pôle Vieillessement, Réadaptation et Accompagnement : AP-HP, Hôpital Universitaire Paul Brousse, 14 Avenue Paul Vaillant Couturier, 94800 Villejuif ; 13. CHU Brabois Avenue de Bourgogne 54500 Vandoeuvre les Nancy, France. Corresponding author: Professor Yves Rolland, Service de Médecine Interne et de Gérontologie Clinique, Pavillon Junot, 170 avenue de Casselardit, Hôpital La Grave-Casselardit, 31300 Toulouse, France. Tel.: (33) 5 61 77 74 65; Fax: (33) 5 61 49 71 09 Email: rolland.y@chu-toulouse.fr

Abstract: *Objective:* The aim of this review of the literature is to report the factors which both contribute to the frailty syndrome and increase hip fracture risk in the elderly. This work is the fruit of common reflection by geriatricians, endocrinologists, gynecologists and rheumatologists, and seeks to stress the importance of detection and management of the various components of frailty in elderly subjects who are followed and treated for osteoporosis. It also sets out to heighten awareness of the need for management of osteoporosis in the frail elderly. *Design:* The current literature on frailty and its links with hip fracture was reviewed and discussed by the group. *Results:* The factors and mechanisms which are common to both osteoporosis and frailty (falls, weight loss, sarcopenia, low physical activity, cognitive decline, depression, hormones such as testosterone, estrogens, insulin-like growth factor-I (IGF-I), growth hormone (GH), vitamin D and pro-inflammatory cytokines) were identified. The obstacles to access to diagnosis and treatment of osteoporosis in the frail elderly population and common therapeutic pathways for osteoporosis and frailty were discussed. *Conclusion:* Future research including frail subjects would improve our understanding of how management of frailty can contribute to lower the incidence of fractures. In parallel, more systematic management of osteoporosis should reduce the risk of becoming frail in the elderly population.

The term frailty is used by physicians caring for elderly persons to describe a patient at high risk of becoming dependent, of comorbid illnesses, admission to an institution and mortality. This term often reflects a physician's subjective perception of the patient's state of vulnerability. For some authors, frailty expresses an acceleration in the aging processes (1). For others, frailty is a pathological state that has its own pathophysiological mechanisms which are distinct from those of advancing age (2). Although the clinical reality of the concept of frailty is recognized by the whole scientific community, there is no generally accepted definition. Nevertheless, the central element defining frailty is a state of great vulnerability of an aged subject when confronted by a stressor. The causes appear to be varied and to differ in importance according to the individuals. Frailty is thought to be related to multiple deficiencies (Figure 1) which interact between themselves and lead to a decrease in physiological reserves (3-5).

Typically, frail patients lack strength, tire easily, are generally inactive and move slowly. They have little appetite and have recently lost weight. Their morale is poor and their cognitive functions are in decline. These symptoms are present in varying degrees. Although often found in association, frailty

is distinct from comorbid illnesses, which are above all factors that hasten the frail subject's transition into disability (Figure 2). In practice, the concept of frailty can provide an explanation for the considerable differences in tolerance of stress between one aged subject and another. At the same age, and faced by the stress of pulmonary disease, bereavement, a fall or admission to hospital, the outcome will be much more unfavorable in the frail than in the robust elderly subject.

Identification of the clinical characteristics of the frailty syndrome (Figure 1) has been the theme of several expert meetings (6-9). Decreased strength, a feeling of tiredness, involuntary weight loss, slowness and inactivity appear as the key domains, to which various teams add social isolation and comorbid conditions, among which depression and cognitive deficiencies are proposed. Although all these factors are recognized as determinant in the frailty syndrome, adoption of a practical clinical definition is still difficult (6,8,10-13). In 2001, Fried et al. proposed an operational approach to the phenotype of frailty (Figure 3). Although there is no consensus, the majority of contemporary studies are based on these criteria or their adaptation.





FRAILITY, OSTEOPOROSIS AND HIP FRACTURE

Figure 1





Figure 2


Relations between frailty, disability and comorbid illnesses



Adapted from Fried et al. (5)

Figure 3

Criteria of frailty proposed by Fried et al., 2001 (5)




The growing interest in the concept of frailty is related to its reversible nature (Figure 4, (12)). While frailty is highly predictive of a certain number of adverse events, it is also amenable to interventions. Early detection and early, often simple measures for management of frailty can prevent transition into disability. Once disability has set in, on the other hand, it is rarely reversible in spite of difficult and costly interventions.

In the absence of a generally accepted definition, it is difficult to judge the exact prevalence of the frailty syndrome. Depending on the criteria of frailty used, its prevalence may vary three-fold (14). The prevalence of frailty also depends on the characteristics of the population studied. All studies agree in emphasizing the importance of the public health problem that it represents (Table 1).

Figure 4

Outcome at 18 months of subjects classified by the criteria of Fried et al.



Adapted from Gill et al., 2006 (12)


The literal meaning of the Anglo-Saxon term also signifies that the frail subject « breaks easily ». Exposed to the stress of a fall, he or she has a high risk of fracture, and thus of transition to disability, institutionalization, comorbid illnesses and death. The osteoporotic subject therefore seems to be, in the geriatric sense, a frail subject. Paradoxically, no current definition of frailty includes bone mineral density (BMD) (7). Various authors have however highlighted the frequent association between osteoporosis and frailty (15). Osteoporosis appears to be a good marker of frailty. It is a sign of vulnerability.

Hip fracture is the major complication confronting elderly subjects and this too is a major public health problem. Frail subjects seem to be particularly exposed to this complication, which may be predicted a few years beforehand by a so-called « sentinel » fracture of the wrist (16). The incidence of hip fracture rises from 1.6 per 1 000 at the age of 65 years to 35.4 per 1 000 at the age of 95 years (17). Mortality ranges from 35% at 12 months (18) to 10% at 2 years (19) depending on the cohorts. Of those patients who do not die, the majority never regain their earlier functional performances (20,21). Hip fracture exposes the aged subject to pain, depression, reduced physical activity, weight loss and hypercatabolism. During hip fracture, the aged subject often transitions to disability.

The notion that the frail subject is at particular risk of hip fracture is a recent one (22). Yet frailty and its accompanying mechanisms such as inactivity, decreased strength and weight loss are associated conditions known to hasten the onset of osteoporosis (23) and increase the likelihood of falls and fractures. Independently of BMD, recent works have shown that frailty is a major risk factor for falls (OR=2.41, 95 CI%, 1.93-3.01) (22). The number of falls is in itself a major risk factor for hip fracture, independently of BMD (24). As the frail subject is at risk both of osteoporosis and above all of falls, he or she presents all the prerequisites for hip fracture. Ensrud et al. have shown that their fracture risk was higher than that of nonfrail elderly subjects of the same age (OR=1.70, 95% CI, 1.35-2.15) (22).

It is important to understand the links between frailty, osteoporosis and hip fracture as the therapeutic approaches may be different or complementary. The efficacy, cost and adverse effects of a purely pharmacological approach aiming to increase BMD or of a multidisciplinary approach aimed at countering the factors associated with frailty (malnutrition, inactivity, weakness...) may be very different in a frail or a





THE JOURNAL OF NUTRITION, HEALTH & AGING©

robust aged population (25). Faced with these issues, it is for example necessary to determine in aged persons the influence which may be imputed to decreased BMD in the occurrence of a fracture as compared with other fracture risk factors (25) such as falls and their multiple causes.

At the present time, few elderly subjects have the benefit of a diagnostic and therapeutic approach aimed at estimating their hip fracture risk. Approaching osteoporosis through the frailty syndrome would not only encourage access to investigation and treatment of osteoporosis but would also give frail subjects the benefit of a therapeutic approach adapted to their health status.

Screening and management of selected factors associated with frailty would certainly have a major impact on hip fracture risk by limiting the risk of falls, disability and decreased BMD and by opening up access to the diagnosis and treatment of osteoporosis.

The aim of this review of the literature is to report on the factors which both contribute to the frailty syndrome and increase hip fracture risk in the elderly. By emphasizing the complementary nature of geriatric and rheumatological management, this work, which is the fruit of common reflection by a group of geriatricians, endocrinologists, gynecologists and rheumatologists, aims to increase awareness of the importance of detection and management of the various components of frailty in elderly subjects who are followed and treated for

osteoporosis. It also sets out to heighten awareness of the need for management of osteoporosis in the frail elderly.

Factors and mechanisms common to osteoporosis and frailty

Falls

Various reviews underline the highly heterogeneous nature of fracture risk factors in the aged, differing between individuals (26, 27). In frail subjects, several factors expose them to multiple falls (28). The data of the literature suggest, moreover, that fracture risk is related to the high frequency of falls rather to low BMD.


In an institutional setting, the high incidence of falls is the determining factor in the onset of hip fractures, more than low BMD (29). Fracture risk is greatest when a high risk of falls and low BMD are present concurrently. Risk of hip fracture is nearly 25 times higher in elderly women with a history of both a recent fall and osteoporosis than in those with neither a fall nor decreased BMD (30). Frail subjects who associate factors contributing to a decrease in BMD and multiple falls thus seem to be particularly exposed to hip fracture (Figure 3). This explains why the fracture risk is higher in a frail elderly population (30-32).

At the present time, the part played by falls and low BMD in

Table 1
Prevalence of the frailty syndrome according to the populations and criteria used in some studies of frailty

Name of study	Population	Criteria of frailty	Frail (%)	References
Osteoporotic Fractures in Men Research Group	5993 men aged 65 or older living at home	Sarcopenia, fatigue, weakness, low activity, slow walking speed	4	Cawthon et al. 2007 (161)
Comparison of studies	309 cardiology inpatients aged 70 or older	Fried et al. versus Rockwood et al.	27 versus 63	Purser et al. 2007 (162)
InCHIANTI study	827 subjects aged 65 or older living at home	Fried et al. adapted	6.5	Ble et al. 2006 (163)
Precipitating Events Project	754 subjects aged 70 or older living at home	Fried et al. adapted	25.7	Gill et al. 2006 (12)
Women's Health Initiative Observational Study	40 654 women aged 65 – 79 living at home	Fried et al. adapted	16.3	Woods et al. 2005 (164)
Hispanic Established Population Epidemiological Study of the Elderly	621 subjects aged over 70 living at home	Fried et al. adapted	20	Ottenbacher et al. 2005 (165)
Canadian Study of Health and Aging	9008 subjects aged 65 or older living at home	Physical activity, disability, cognition	4.4% of subjects aged over 85 very frail	Rockwood et al. 2004 (166)
EPIDOS study	7574 women aged over 75 living at home	One or more IADL disability	32	Nourhashémi et al. 2001 (167)
Cardiovascular Health Study	5317 subjects aged 65 or older living at home	Fried et al.	6.9	Fried et al. 2001 (5)





FRAILITY, OSTEOPOROSIS AND HIP FRACTURE

the occurrence of fractures in the frail population has not been defined. Its determination is however of practical interest, for the therapeutic approach is not the same. In the EPIDOS study, the relationship between BMD and hip fracture rate decreased with age (33). The Study of Osteoporotic Fractures (SOF) (34) made similar findings. In the European Prospective Osteoporosis Study, BMD was less predictive of hip fracture risk than was an increased rate of falls (35). In the Fracture Risk Epidemiological in the Elderly (FREE) Study, fall frequency was the determinant factor in fracture risk (29). A study of nursing home residents by Greenspan et al. demonstrated that fracture risk was more strongly correlated with fall characteristics (OR 5.7; 95% CI 1.7-13; $p=0.003$) and impaired mobility (OR 3.5; 95% CI 1.1-11; $p=0.04$) than with low BMD (OR 1.9; 95% CI 1.1-3.2; $p=0.02$) (25). In another population of 3 886 women aged over 80, selected for their high fall risk, the group treated with risedronate did not experience fewer hip fractures (34).

It should be noted, moreover, that fracture risk may be higher in frail subjects than in ill subjects who are already dependent and have impaired balance. This paradox may be explained by the higher frequency of falls in frail subjects than in already dependent subjects (36). Dependent subjects may take less risks and engage in less at-risk activities than frail subjects.

Weight loss

Among predictors of weight loss, reduced protein and energy intake is a factor of osteoporosis and of frailty. Weight loss is a criterion of frailty in the elderly subject (37). Reduced food intake, in particular of protein, hastens transition to frailty and also osteoporosis (38). Changes in femoral neck BMD accompany weight changes in postmenopausal women (39). BMD is also associated with markers of nutritional status such as serum albumin (40-42). These relations explain why subjects with hip fracture generally have lower body weight than subjects of the same age without fracture (43).

In 1995, Cummings et al. already reported from the findings of the Study of Osteoporotic Fractures (SOF) that weight loss was an independent and reversible risk factor of fracture (44). In both men and women, weight loss increases fracture risk (45, 46). Some studies have suggested that the threshold of 10% weight loss increases fracture risk two-fold (RR=1.8; 95% CI 1.04-3.3). Importantly, a 10% gain of body weight has a protective effect (45).

It is however difficult to know whether fracture risk is increased because of a thinner fatty layer which poorly absorbs impact energy, or whether low body weight reflects low bone density and quality as well as poor nutritional status. Some studies have reported an association between low body mass index ($BMI = \text{weight}/\text{height}^2$) and increased hip fracture risk (47), and have suggested that fracture risk is related to the severity of the impact of the injury, which is greater if the patient is tall.

Sarcopenia

Among the important changes in body composition which are associated with aging, sarcopenia is one of the major domains which characterize frailty. The term sarcopenia was initially introduced by Rosenberg in 1989 and applied to the progressive wasting of muscle mass during aging (48). The present definition of sarcopenia comprises reduced muscle strength, mass and quality. Sarcopenia is an important field of research in geriatrics as it is considered to bear considerable responsibility for functional limitations and motor dependency in elderly persons.

Subjects who have difficulty in carrying out certain motor tasks such as chair rises or standing for a long while without fatigue have a higher risk of hip fracture (44). Impaired mobility is a fracture risk factor in the elderly population (25) in addition to low BMD and a high fall risk. Lack of strength (49,50), slow gait speed (24), and poor balance are conditions which reflect the patient's frailty and are predictive of fractures (51).

Muscle mass declines by about 1 to 2% per year after the age of 50 (52). Strength declines by 1.5% per year between the ages of 50 and 60 then by 3% per year subsequently (55-56). There is no consensual definition of sarcopenia. However, it is estimated that about 20% of men aged 70 to 75 and about 50% of subjects aged over 80 have sarcopenia. Among women, 25 to 40% in the same age ranges are sarcopenic. Janssen et al. reported that 35% of elderly subjects were moderately and 10% severely sarcopenic (57). For Melton et al., 6 to 15% of subjects aged over 65 are affected (58). In the EPIDOS cohort of home-dwelling women aged over 70, about 10% are sarcopenic (59). Whatever the study, however, all describe very great disparity between individuals of the same age.

Sarcopenic subjects are also those who have lower BMD and a higher risk of falls (58,60,61). Among postmenopausal women, 25% of osteopenic women and about 50% of osteoporotic women are sarcopenic (62). This association between low muscle mass and low BMD has been reported in various studies (63-68).

Decreased BMD could be due in part to decreased bone stress associated with the reduced physical activity observed in elderly persons (69). The decrease in physical activities and in particular resistance activities promote muscle wasting, which is itself associated with the decrease in BMD. Inactivity is also associated with impaired balance and reduced coordination and suppleness, which all contribute to the risk of falls.

Cognitive decline and depression

Cognitive decline is often considered as a characteristic factor of the frailty syndrome and a fall risk factor. Falls are very frequent in patients with impaired higher functions (70-72). Prospective studies have reported that falls were twice as frequent as in subjects of the same age without cognitive impairment. These falls explain why 3 to 7 times more hip fractures are observed in patients with Alzheimer's disease,





THE JOURNAL OF NUTRITION, HEALTH & AGING©

even in the earlier stages of the illness (70, 73). Fall mechanisms, more than low BMD, are the cause (73).

Cognitive decline may contribute to the relation between the frailty syndrome and fractures. Frail subjects with poor functional performances (slow walking speed) are also at risk of cognitive decline. Recently, Wang and collaborators (74), in a prospective study of 2 288 participants, showed that motor performances were predictors of dementia and of Alzheimer's disease in particular. A possible hypothesis is that poor motor performances reflect a low level of physical fitness, which is in itself associated with the risk of dementia (75). These findings support the notion that the decline of functional performances such as walking or balance precede cognitive decline, also a predictor of falls (76).

Hormones

It is now widely recognized that frailty reflects deficiencies of various systems, among them dysregulations of the endocrine system and overexpression of pro-inflammatory cytokines (Figure 1). These mechanisms are common to both frailty and osteoporosis.

Decreased testosterone is often cited as an important factor of frailty in aging men (13). In the elderly subject the andropause is associated with muscle mass and could be implicated in the decrease of BMD. However, the majority of epidemiological studies do not support this association between serum testosterone levels and BMD (77,78) and the few interventional studies do not report an increase in BMD in hypogonadal men treated with testosterone (79). The marked decrease in estrogens during the menopausal period and the rise in cortisol observed during aging also contribute to modify body composition to the detriment of muscle mass.

Insulin-like growth factor-I (IGF-I) and growth hormone (GH) also decline with age (52) and these two hormones could be risk factors for frailty (via sarcopenia) and osteoporosis. GH treatment decreases fat mass and increases lean mass and BMD (80,81). In elderly women, a positive association has been reported between GH levels and BMD (82). GH may also have a direct modulating effect on vitamin D receptors (83).

However, the effect of GH on strength remains debated (84-89) as the increase in muscle mass appears to be related to sodium and fluid retention. Its side effects also restrict its use. At the present time and in spite of the probable relations between GH, IGF-I, muscle mass and bone tissue, the benefits of GH remain to be demonstrated, on muscle as well as on bone.

During the last 15 years, numerous works have reported the role of pro-inflammatory cytokines such as IL-6 in the development of sarcopenia (90). The rise in IL-6 could also be implicated in other disorders which are frequent during aging, among them osteoporosis (91).

Lastly, the importance of vitamin D deficiency and probably of secondary hyperparathyroidism has been widely debated in the scientific literature. Vitamin D status and inactivity play a

decisive role in the risk of osteoporosis and of falls (92,93). They will be discussed in the section on treatment.

Prevention and treatment


Access to diagnosis and treatment of osteoporosis

In the absence of a consensual definition of frailty, the proportion of frail elderly subjects who have osteoporosis and who receive treatment is not known at the present time. However, it is probable that few frail elderly patients have the advantage of pharmacological treatment for osteoporosis. Our knowledge of subjects beyond the frailty syndrome such as residents of institutions, who are generally dependent, highlights the lack of diagnosis and treatment of osteoporosis (94, 95). In 2007 and in spite of awareness-raising campaigns on osteoporosis, the great majority of subjects who have had an osteoporotic fracture are not treated for the disease (96). Only one in two institutionalized osteoporotic subjects receive calcium and/or vitamin D supplements (97). In spite of national recommendations (95, 98), only 18% of patients with fractures are given vitamin and calcium supplements (99). This is a regrettable situation, since on the other hand we know the devastating consequences of hip fractures on the quality of life, morbidity and mortality of the most vulnerable aged subjects (32).

In 2004, a group of experts listed the barriers to access to osteoporosis treatments (95) of elderly subjects living in institutions. The characteristics of the frail subject differ from those of institutionalized subjects. However, the reasons put forward are certainly very similar to those which restrict the prescription of a treatment for osteoporosis in frail subjects. These reasons are not based on any rationale. The inutility of a long-term treatment, on account of the patients' low life expectancy, is sometimes mentioned. However, according to the criteria of Fried et al. (5), the mortality at 18 months of frail subjects is 13.5% (12), whereas the benefit of treatment is already significant at 6 months (93). The idea generally held by geriatricians is that non-pharmacological and in particular nutritional management take precedence at this age. However, this does not exclude recourse to medication. Observance is a major problem in the treatment of osteoporosis (100) but has no reason to be poorer in the frail elderly. Tolerance of treatment is usually good. Lastly, polypharmacy, which is often cited to avoid adding another item to an already lengthy prescription, must above all be discussed in terms of risk/benefit ratio. It is estimated that the risks related to untreated osteoporosis exceed those related to treatment (95).

Another barrier to osteoporosis management is the question of access to bone density measurement by dual energy X-ray absorptiometry (DXA). DXA is the gold standard complementary investigation to establish the diagnosis of osteoporosis. At the present time there is no clinical test or evaluation scale which can replace it. A subject with a T-score more than 2.5 standard deviations below that of a young





FRAILTY, OSTEOPOROSIS AND HIP FRACTURE

reference population at the lumbar spine or femoral neck is considered as osteoporotic. DXA is simple to perform, reliable, reproducible and without risk. Ultrasound of the calcaneum can be used to estimate fracture risk but at the present time it is in no way an investigation which could replace DXA measurement. Moreover, no therapeutic trial has been carried out in populations selected in this manner. The sensitivity of ultrasound in the selection of osteoporotic subjects aged over 65 was only 61%, which greatly diminishes its value both in research and in clinical practice (101).

The majority of studies on osteoporosis presume that subjects lost to follow-up are comparable to the rest of the cohort. In fact, they are often frail subjects with restricted mobility. These frail subjects introduce significant bias resulting in underestimation of BMD decrease in the cohort (102). The difficulty of following frail patients generally leads investigators to exclude the most vulnerable subjects from clinical research studies. It is therefore often difficult for practitioners to recognize in the current literature on osteoporosis the frail elderly subjects they have in their care.

We consider, however, that frail subjects particularly exposed to the risk of falls, osteoporosis and so of fractures certainly form a target population which could benefit both from more systematic screening for osteoporosis and from pharmacological treatment of the condition. In the absence of contemporary data specifically concerning this population, these recommendations will need to be validated by future research studies.

Common therapeutic pathways for osteoporosis and frailty


As far as we are aware, there are no specific recommendations on management of osteoporosis in the frail elderly. National recommendations on diagnostic and therapeutic procedures for osteoporosis in institutionalized patients have been issued in Quebec and in the United States. These recommendations concern elderly subjects who are already dependent. However, they stress the value of the usual therapeutic regimens and also that of non-pharmacological management (95, 98).

The frailty syndrome, falls and osteoporosis share common determining factors (Figure 5) that contribute to the occurrence of hip fracture. In frail subjects, management of factors such as weight loss, inactivity, decreased muscle strength and fatigue in association with treatments aiming to increase BMD are rarely seen as a priority in clinical practice.

Non-pharmacological treatment

Numerous studies have shown that non-pharmacological management of elderly subjects, even in institutions, would make it possible to reduce the number of falls and especially of fractures (103).

Figure 5
Usual factors of frailty, falls and osteoporosis



* Short Physical Performance Battery (SPPB), proposed consensual walking speed

Physical activity

Physical activity can have three main beneficial effects in prevention of hip fracture in frail subjects: increased BMD, improved strength and better balance, effectively reducing the risk of falls.

Increased BMD

Throughout life, bone and muscle adapt to the mechanical strains to which they are subjected. Regular physical activity increases not only muscle mass but also bone mass (104). Observational findings all corroborate the association between an active life and high BMD. However, interventional studies, probably because of their insufficient duration, do not always confirm the cause-to-effect relation between subjection of bone to mechanical stress and the increase in BMD. This emphasizes above all the importance of long-term management.

The mechanical stress exercised by muscle groups on bone structures generate in response an increase in BMD. Various works have reported a positive correlation between muscle mass or strength and BMD (63, 66, 67). Athletes or former athletes have higher BMD than inactive subjects (105). However, bone response only occurs in the site involved and is not a systemic phenomenon. The increase of muscle mass is associated with bone of larger diameter and thicker cortical bone (78, 106), probably due to increased periosteal apposition (107, 108). These anatomic changes in bone are associated with greater resistance to compression, which is often the mechanism implicated in fractures (long bones, radius, vertebrae) (67).

However, even if most randomized studies have demonstrated that participation in physical activity could increase BMD in elderly subjects (109,110), some found no significant differences (111) and the great majority of works included healthy subjects without frailty syndrome. Only one study investigated the effects of a physical exercise program on





THE JOURNAL OF NUTRITION, HEALTH & AGING©

BMD in 112 frail subjects defined by poor endurance, poor functional performances and difficulties in one ADL or two IADL (112). After a physical activity program lasting 9 months and including resistance exercises, endurance, suppleness and balance training, BMD was similar to that of a group following a low-intensity exercise program (112). It appears that an adequate threshold of bone stress, and thus of intensity of physical exercise, must be reached in order to stimulate bone formation (113). Some works also suggest that the threshold of mechanical stimulation required to promote BMD increase is higher with lower estrogen levels (114). At the present time, the modalities of the physical activity regimen of frail elderly subjects which would make it possible to increase BMD are yet to be defined and the benefits of physical activity on the bones of frail elderly subjects remain to be demonstrated (112).

Improving strength and balance to reduce fall risk

Increasing activity appears to be a simple and effective means of countering fall risk factors such as muscle weakness, functional limitations or fatigue, all of which are associated with frailty. Specific training can improve strength, balance and coordination (115, 116) and contribute to resumption of an active life by reducing fear of falling (117). For more than twenty years, various teams have shown that an intervention focusing on the practice of a physical activity reduced hip fracture risk by about half (118, 119). Tai chi is probably the activity which has received most attention in this domain (116). Activity can also yield a positive effect in frail subjects (120), in whom such non-pharmacological management is particularly indicated. In these subjects at risk of falls, a realistic exercise program improves balance, strength, suppleness and endurance and reduces the number of falls (121, 122).

Body composition

Sarcopenia is a determining factor in frailty, and is often associated with osteoporosis and falls. The decrease in muscle mass is secondary to multiple factors, among them decreased protein and energy intake (122). In frail subjects, who are often malnourished, low protein intake slows the synthesis of muscle tissue and strength increase. Various works consider that in association with adequate energy intakes, the protein intakes of more than 1 g/kg/day which are traditionally recommended are a minimum, particularly in frail subjects, to minimize sarcopenia (123).

In subjects who are well, who are not malnourished, protein supplementation is not associated with an increase in muscle mass or in strength. Even in association with a physical activity program, most randomized studies on the effect of protein supplementation in the robust elderly yielded negative findings (see 124 for references).

Bone tissue is also dependent on nutritional status. Numerous works have reported inadequate calcium and vitamin D intakes in elderly subjects, in particular among the most

vulnerable. Protein intake has also a decisive impact on bone quality. A recent review of the literature concluded that bone resorption decreased when protein supplements were given to osteoporotic subjects living at home (125).

These findings highlight the value of nutritional management, particularly in frail subjects. As far as we are aware, no study has specifically addressed the issue of the impact of long-term nutritional management of frail subjects on the risk of osteoporosis, falls and fractures.

Hip protectors


Hip protectors are a non-pharmacological approach which may be envisaged to reduce the fracture risk of falls. A recent literature review published in the BMJ suggested that hip protectors were effective in institutionalized subjects, which is the section of the aged population at highest risk of falls (126). A short time previously, a paper in the same journal concluded that hip protectors were ineffective (127). A study published in August 2007 in JAMA and carried out in over 1 000 residents in 37 nursing homes did not confirm a protective effect on fracture risk (128). Methodological differences (randomization by cluster, by patient, by hip) account for these conflicting results. It appears however that in institutionalized subjects at highest risk of falls hip protectors are a simple and useful option, whose main drawback is mediocre adherence. In the light of these findings, the frail elderly, most of whom live at home and have a lower fall risk than those in institutions, are probably not a target population which would benefit from wearing hip protectors.

Pharmacological treatment

Vitamin D

Vitamin D insufficiency is defined as a level less than 25 nmol/l (or <10 ng/ml) and deficiency as less than 12.5 nmol/l (or <5 ng/ml) (25 (OH)D measurement with organic extraction and high pressure liquid chromatography, HPLC). Differences in exposure to sunshine and in dietary intake of vitamin D, which complete endogenous production, explain why the prevalence of insufficiency and deficiency varies greatly between different populations. About 15% of the general adult population have vitamin D insufficiency (129,130). Vitamin D insufficiency affects 50% of women aged 65 or over in France (131). It is often complicated by osteomalacia and concerns 70 to 100% of the institutionalized population (132). In spite of these figures, few elderly persons have an adequate vitamin intake, particularly among the most frail elderly. Yet the value of vitamin D supplementation could be even greater in a less active population at high risk of falls (92). In an institutional setting, vitamin D (700 to 800 IU) in association with calcium slightly reduces hip fracture risk according to most authors (93,133). In a more independent elderly population, living at home, the most recent studies have not confirmed these results,





FRAILITY, OSTEOPOROSIS AND HIP FRACTURE

even in association with calcium (134,135). Fracture risk is the result of more or less frequent falls and a decrease in BMD. These divergent results could be explained by the preventive effect of vitamin D on fall frequency. It has in fact been shown that vitamin D reduces fall risk by about 20% and by up to 65% in women (92). As secondary prevention, in patients who have presented a femoral fracture, the association of calcium and vitamin D is no longer adequate, and specific treatment for osteoporosis is required (bisphosphonates or strontium ranelate).

The preventive effect of vitamin D on falls may be related to its effect on muscle. Various observational studies have reported an association between low vitamin D levels and low muscle mass, muscle weakness, impaired balance and increased fall risk (78,93,136-138). Visser et al. also showed in a longitudinal study that a low vitamin D level was a predictor of sarcopenia (139). The effect of vitamin D supplementation on muscle strength and fall frequency in elderly women is currently being evaluated in a randomized controlled study.

Low vitamin D is often associated with a high level of parathyroid hormone (PTH). Some studies also suggest that secondary hyperparathyroidism is a contributory factor of sarcopenia, independently of vitamin D levels (139,140), and is a risk factor for falls (141). Parathyroid hormone has however rarely been studied in the frail elderly population (142).

The dose and modalities of vitamin D administration are still debated. The dose of 800 IU/day of cholecalciferol is certainly more appropriate than the 400 IU previously recommended. However, this supplementation does not take account of individual disparities. The findings of the prospective OPRA study suggest that below the threshold serum level of 20 ng/ml of 25-hydroxy vitamin D, the fall risk increases significantly (143) and the optimal level to be reached is about 30 ng/ml.

Bisphosphonates and strontium ranelate

The value of bisphosphonates and strontium ranelate has been demonstrated in cohorts of osteoporotic subjects. There are no specific data on frail subjects. With regard to dependent subjects, a symposium of experts concluded that pharmacological treatment of osteoporosis was justified even in this population (95). Only one study of bisphosphonates has been carried out in an institutional setting, where fall risk is known to be high. This work did not enable a conclusion to be drawn because the series was too small (144). Only analyses of findings in the most aged subjects in existing cohorts, which certainly contain the largest proportion of frail subjects, make it possible to study the effect of pharmacological treatment in the frail elderly. In women aged 70 to 80 years with known osteoporosis, risedronate reduced hip fracture risk by 40% (34). In an analysis of a subgroup of osteoporotic subjects aged over 80 years in the TROPOS and SOTI studies, strontium ranelate also significantly reduced the risk of vertebral and non-vertebral fractures (145). A yearly infusion of zoledronic acid

within 90 days after an osteoporotic hip fracture also reduced the incidence of new fractures and mortality (19). These few data suggest that in frail subjects, fracture risk can be reduced by pharmacological management. These arguments support the value of primary or secondary therapeutic management.

Estrogens

The Women's Health Initiative (WHI) has demonstrated the benefits and the limitations of hormone replacement therapy (HRT) (146). Estrogens are thus not usually envisaged as a treatment of osteoporosis in the frail elderly population. Very few studies have observed the effect of estrogens on bone mineral density in frail elderly subjects. The existing studies have however reported increased BMD of the lumbar spine (+4%) and hip (+2%) (147). This effect may be enhanced if the subjects follow an exercise program, whether they are postmenopausal women (148) or women who already present criteria of frailty (114). This additive effect of exercise and HRT seems, however, to affect only trabecular vertebral bone (114, 148).

Other works have also demonstrated the beneficial effect of estrogens on muscle mass and strength (114). A review of the literature has recently been published on the effects of estrogens on body composition and strength (149). Estrogens may increase muscle strength but may have no effect on muscle mass. Hormone replacement therapy may have a direct action on nuclear receptors of muscle fiber and increase vitamin D levels (150,151). However, these results relate to menopausal women and are not confirmed in subjects aged over 60 (149).


Selective estrogen receptor modulators (SERMs) are another alternative treatment which has been very little studied in frail subjects. A study using SERMs in institutionalized patients did not however report a decreased number of hip fractures in treated subjects even though their BMD increased (152). Moreover, little is known of the safety of SERMs in the elderly population.

Androgens

Various anabolic molecules can be envisaged to increase muscle mass in frail subjects.

About 20% of men aged over 60 and 50% of men aged over 80 are considered to be hypogonadal. Testosterone concentration declines by 110 ng/dL on average every 10 years (153). At the present time, studies of the effects of testosterone on muscle mass and strength in elderly subjects have yielded divergent results. Muscle mass increases in young subjects taking supraphysiologic doses and carrying out resistance exercises (154). Such doses cannot however be envisaged in elderly subjects because of the adverse effects, in particular the risk of prostate cancer. Some studies have reported a modest increase in muscle mass but the majority found no increase in strength (see 124 for references). The increase in strength





THE JOURNAL OF NUTRITION, HEALTH & AGING®

reported in some studies is markedly lower than the increase in strength which may be expected through a resistance exercise program. In view of this, use of testosterone is not recommended in the elderly at the present time. The DHEAge study also reported no beneficial effect on muscle mass or strength (155). Other molecules with an anabolic effect such as 7 alpha-methyl-19-nortestosterone (MENT or trestolone), selective androgen receptor modulators (SARMs) or teriparatide, but which do not have the adverse effects of testosterone, are being experimented.

Numerous questions remain as to the value and safety of GH in elderly subjects. In subjects with GH deficiency secondary to hypopituitarism, GH supplementation increases muscle mass (84) through increased production of IGF-I and of form 3 of its carrier protein (IGFBP-3). This effect is dependent on the subject's nutritional status. Critically ill patients have low IGF-I levels in spite of high GH levels (156). GH supplementation after hip fracture in elderly subjects induces an elevation in serum levels of the hormone but the elevation is less as the severity of illness is greater (157). This peripheral resistance to GH is not observed in well subjects (158). As frail subjects would be those most likely to benefit from GH supplementation, this observation limits the potential scope of such treatment. In another respect, GH supplementation results in a higher mortality rate in malnourished elderly subjects (159). Numerous adverse effects have been reported in treated subjects (arthralgias, edema, adverse cardiovascular effects and increased insulin resistance), leading to numerous dropouts (89). At the present time, the data of the literature do not allow us to envisage this treatment in frail subjects.

Conclusion

The frail patient is at high risk of hip fracture. However, he has little access to organized fall prevention measures, nor to the diagnostic and therapeutic approach to osteoporosis. The concept of frailty opens up a different approach to hip fracture risk in the elderly. Prevention and care organization appear as pertinent perspectives in this population. The classic model in which each disorder is treated individually is poorly adapted to management of the frail subject. The therapeutic approach to osteoporosis directed at increasing BMD is necessary but probably inadequate in this population (160). The aim of treatment cannot be restricted to obtaining an increase in BMD. Fall prevention by improving muscle strength, balance, nutritional status and cognition are therapeutic means which should limit the incidence of fractures.

Further studies including frail subjects would improve our understanding of how management of frailty can have an impact on fractures. In parallel, more systematic management of osteoporosis should reduce the risk of becoming frail or of hastening the transition from frailty to disability in the elderly.

Acknowledgements: The authors acknowledge the financial support of the "Institut de Recherches Internationales Servier, IRIS".

References

- Mitnitski AB, Mogilner AJ, MacKnight C, Rockwood K. The accumulation of deficits with age and possible invariants of aging. *ScientificWorldJournal*. 2002 Jun 28;2:1816-22.
- Fried LP, Walston J. Frailty and failure to thrive. In: W.R.Hazzard, J.P. Blass, J.B. Halter et al. editor. *Principles of geriatric medicine and gerontology*. USA: McGraw Hill, 2003;1487-1502.
- Lipsitz LA, Goldberger AL. Loss of 'complexity' and aging. Potential applications of fractals and chaos theory to senescence. *JAMA*. 1992 Apr 1;267(13):1806-9.
- Bortz WM 2nd. The physics of frailty. *J Am Geriatr Soc*. 1993 Sep;41(9):1004-8.
- Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci*. 2001 Mar;56(3):M146-56.
- Hogan DB, MacKnight C, Bergman H, on behalf of the steering committee Canadian Initiative on Frailty and Aging. Models, definitions, and criteria of frailty. *Aging Clin Exp Res*. 2003;15(3 Suppl):1-29.
- Ferrucci L, Guralnik JM, Studenski S, Fried LP, Cutler GB Jr, Walston JD; Interventions on Frailty Working Group. Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. *J Am Geriatr Soc*. 2004 Apr;52(4):625-34.
- Walston J, Hadley EC, Ferrucci L, Guralnik JM, Newman AB, Studenski SA, Ershler WB, Harris T, Fried LP. Research agenda for frailty in older adults: towards a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research conference on frailty in older adults. *J Am Geriatr Soc* 2006;54:991-1001.
- Bergman H, Ferrucci L, Guralnik J, Hogan DB, Hummel S, Karunanathan S, Wolfson C. Frailty: an emerging research and clinical paradigm--issues and controversies. *J Gerontol A Biol Sci Med Sci*. 2007 Jul;62(7):731-7.
- Morley JE, Perry III HM, Miller DK. Something about frailty. *J Gerontol Med Sci* 2002;57(A):11:M698-M704.
- Rockwood K. Frailty and its definition: a worthy challenge. *J Am Geriatr Soc* 2005;53:1069-1070.
- Gill TM, Gahbauer EA, Allore HG, Han L. Transitions between frailty states among community-living older persons. *Arch Intern Med*. 2006 Feb 27;166(4):418-23.
- Morley JE, Haren MT, Rolland Y, Kim MJ. Frailty. *Med Clin North Am*. 2006 Sep;90(5):837-47.
- van Iersel MB, Rikkert MG. Frailty criteria give heterogeneous results when applied in clinical practice. *J Am Geriatr Soc* 2006;54:728-729.
- Crepaldi G, Maggi S. Sarcopenia and osteoporosis: A hazardous duet. *J Endocrinol Invest*. 2005;28(10 Suppl):66-8.
- Cuddihy MT, Gabriel SE, Crowson CS, O'Fallon WM, Melton LJ 3rd. Forearm fractures as predictors of subsequent osteoporotic fractures. *Osteoporos Int*. 1999;9:469-75.
- Jacobsen SJ, Goldberg J, Miles TP, Brody JA, Stiers W, Rimm AA. Hip fracture incidence among the old and very old: a population-based study of 745,435 cases. *Am J Public Health*. 1990 Jul;80(7):871-3.
- Todd CJ, Palmer C, Camilleri-Ferrante C, Freeman CJ, Laxton CE, Parker MJ, Payne BV, Rushon N. Differences in mortality after fracture of hip. *BMJ*. 1995 Oct 14;311(7011):1025.
- Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hylidstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; the HORIZON Recurrent Fracture Trial. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. *N Engl J Med*. 2007 Nov 1;357(18):1799-809.
- Foster MR, Heppenstall RB, Friedenber ZB, Hozack WJ. A prospective assessment of nutritional status and complications in patients with fractures of the hip. *J Orthop Trauma*. 1990;4(1):49-57.
- Magaziner J, Simonsick EM, Kashner TM, Hebel JR, Kenzora JE. Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study. *J Gerontol*. 1990 May;45(3):M101-7.
- Ensrud KE, Ewing SK, Taylor BC, Fink HA, Stone KL, Cauley JA, Tracy JK, Hochberg MC, Rodondi N, Cawthon PM; for the Study of Osteoporotic Fractures Research Group. Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. *J Gerontol A Biol Sci Med Sci*. 2007 Jul;62(7):744-51.
- Ferrucci L, Russo CR, Lauretani F, Bandinelli S, Guralnik JM. A role for sarcopenia in late-life osteoporosis. *Aging Clin Exp Res*. 2002 Feb;14(1):1-4.
- Dargent-Molina P, Favier F, Grandjean H, Baudoin C, Schott AM, Hausherr E, Meunier PJ, Breart G. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. *Lancet*. 1996; Jul 20;348(9021):145-9.
- Greenspan SL, Myers ER, Kiel DP, Parker RA, Hayes WC, Resnick NM. Fall direction, bone mineral density, and function: risk factors for hip fracture in frail nursing home elderly. *Am J Med*. 1998 Jun;104(6):539-45.
- Mautalen CA, Vega EM, Einhorn TA. Are the etiologies of cervical and trochanteric hip fractures different? *Bone*. 1996 Mar;18(3 Suppl):133S-137S.
- Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures.





FRAILITY, OSTEOPOROSIS AND HIP FRACTURE

- Lancet. 2002; May 18;359(9319):1761-7.
28. Runge M, Hunter G. Determinants of musculoskeletal frailty and the risk of falls in old age. *J Musculoskelet Neuronal Interact*. 2006 Apr-Jun;6(2):167-73.
 29. Sambrook PN, Cameron ID, Chen JS, Cumming RG, Lord SR, March LM, Schwarz J, Seibel MJ, Simpson JM. Influence of fall related factors and bone strength on fracture risk in the frail elderly. *Osteoporos Int*. 2007 May;18(5):603-10.
 30. Geusens P, Autier P, Boonen S, Vanhoof J, Declerck K, Raus J. The relationship among history of falls, osteoporosis, and fractures in postmenopausal women. *Arch Phys Med Rehabil*. 2002 Jul;83(7):903-6.
 31. Nevitt MC, Cummings SR. Type of fall and risk of hip and wrist fractures: the study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. *J Am Geriatr Soc*. 1993 Nov;41(11):1226-34.
 32. Girman CJ, Chandler JM, Zimmerman SI, Martin AR, Hawkes W, Hebel JR, Sloane PD, Magaziner J. Prediction of fracture in nursing home residents. *J Am Geriatr Soc*. 2002 Aug;50(8):1341-7.
 33. Hans D, Dargent-Molina P, Schott AM, Sebret JL, Cormier C, Kotzki PO, Delmas PD, Pouilles JM, Breart G, Meunier PJ. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. *Lancet*. 1996 Aug 24;348(9026):511-4.
 34. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. *N Engl J Med*. 2001 Feb 1;344(5):333-40.
 35. Schwartz AV, Nevitt MC, Brown BW Jr, Kelsey JL. Increased falling as a risk factor for fracture among older women: the study of osteoporotic fractures. *Am J Epidemiol*. 2005 Jan 15;161(2):180-5.
 36. Porter RW, Miller CG, Grainger D, Palmer SB. Prediction of hip fracture in elderly women: a prospective study. *BMJ*. 1990 Sep 29;301(6753):638-41.
 37. Rolland Y, Kim MJ, Gammack JK, Wilson MM, Thomas DR, Morley JE. Office management of weight loss in older persons. *Am J Med*. 2006 Dec;119(12):1019-26.
 38. Vanitallie TB. Frailty in the elderly: contributions of sarcopenia and visceral protein depletion. *Metabolism*. 2003 Oct;52(10 Suppl 2):22-6.
 39. Blain H, Carriere I, Favier F, Jeandel C, Papoz L; EPIDOS Study Group. Body weight change since menopause and percentage body fat mass are predictors of subsequent bone mineral density change of the proximal femur in women aged 75 years and older: results of a 5 year prospective study. *Calcif Tissue Int*. 2004 Jul;75(1):32-9.
 40. Orwoll ES, Weigel RM, Oviatt SK, Meier DE, McClung MR. Serum protein concentrations and bone mineral content in aging normal men. *Am J Clin Nutr*. 1987 Oct;46(4):614-21.
 41. Rico H, Revilla M, Villa LF, Hernandez ER, Fernandez JP. Crush fracture syndrome in senile osteoporosis: a nutritional consequence? *J Bone Miner Res*. 1992 Mar;7(3):317-9.
 42. Saito N, Tabata N, Saito S, Andou Y, Onaga Y, Iwamitsu A, Sakamoto M, Hori T, Sayama H, Kawakita T. Bone mineral density, serum albumin and serum magnesium. *J Am Coll Nutr*. 2004 Dec;23(6):701S-3S.
 43. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. *N Engl J Med*. 1987 Nov 5;317(19):1169-74.
 44. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. *N Engl J Med*. 1995; Mar 23;332(12):767-73.
 45. Langlois JA, Visser M, Davidovic LS, Maggi S, Li G, Harris TB. Hip fracture risk in older white men is associated with change in body weight from age 50 years to old age. *Arch Intern Med*. 1998 May 11;158(9):990-6.
 46. Ensrud KE, Ewing SK, Stone KL, Cauley JA, Bowman PJ, Cummings SR; Study of Osteoporotic Fractures Research Group. Intentional and unintentional weight loss increase bone loss and hip fracture risk in older women. *J Am Geriatr Soc*. 2003 Dec;51(12):1740-7.
 47. Greenspan SL, Myers ER, Maitland LA, Resnick NM, Hayes WC. Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. *JAMA*. 1994 Jan 12;271(2):128-33.
 48. Rosenberg IH. Summary comments. *Am J Clin Nutr* 1989;50:1231-3.
 49. Nguyen T, Sambrook P, Kelly P, Jones G, Lord S, Freund J, Eisman J. Prediction of osteoporotic fractures by postural instability and bone density. *BMJ*. 1993 Oct 30;307(6912):1111-5.
 50. Bonnefoy M, Jauffret M, Jusot JF. Muscle power of lower extremities in relation to functional ability and nutritional status in very elderly people. *J Nutr Health Aging*. 2007;11:223-8.
 51. Joseph C, Kenny AM, Taxel P, Lorenzo JA, Duque G, Kuchel GA. Role of endocrine-immune dysregulation in osteoporosis, sarcopenia, frailty and fracture risk. *Mol Aspects Med*. 2005 Jun;26(3):181-201.
 52. Hughes VA, Frontera WR, Roubenoff R, Evans WJ, Fiatarone-Singh MA. Longitudinal changes in body composition in older men and women: role of body weight change and physical activity. *Am J Clin Nutr* 2002;76:473-81.
 53. Evans W. Functional and metabolic consequences of sarcopenia. *J Nutr*. 1997;127:998S-1003S.
 54. Roubenoff R, Hughes VA. Sarcopenia. Current concepts. *J Gerontol A Biol Sci Med Sci* 2000;55A:M716-M724.
 55. Morley JE, Baumgartner RN, Roubenoff R et al. Sarcopenia. *J Lab Clin Med*. 2001;137:231-243.
 56. Vandervoort AA. Aging of the human neuromuscular system. *Muscle Nerve*. 2002;25:17-25.
 57. Janssen I, Baumgartner RN, Ross R et al. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. *Am J Epidemiol*. 2004;159:413-421.
 58. Melton LJ 3rd, Khosla S, Riggs BL. Epidemiology of sarcopenia. *Mayo Clin Proc*. 2000 Jan;75 Suppl:S10-2.
 59. Rolland Y, Lauwers-Cances V, Cournot M, Nourhashemi F, Reynish W, Riviere D, Vellas B, Grandjean H. Sarcopenia, calf circumference, and physical function of elderly women: a cross-sectional study. *J Am Geriatr Soc*. 2003 Aug;51(8):1120-4.
 60. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD. Epidemiology of sarcopenia among the elderly in New Mexico. *Am J Epidemiol*. 1998 Apr 15;147(8):755-63.
 61. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. *J Am Geriatr Soc*. 2002 May;50(5):889-96.
 62. Walsh MC, Hunter GR, Livingstone MB. Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. *Osteoporos Int*. 2006 Jan;17(1):61-7.
 63. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. *Mech Ageing Dev*. 1999 Mar 1;107(2):123-36.
 64. Baumgartner RN, Stauber PM, Koehler KM, Romero L, Garry PJ. Associations of fat and muscle masses with bone mineral in elderly men and women. *Am J Clin Nutr*. 1996 Mar;63(3):365-72.
 65. Gillette-Guyonnet S, Nourhashemi F, Lauque S, Grandjean H, Vellas B. Body composition and osteoporosis in elderly women. *Gerontology*. 2000 Jul-Aug;46(4):189-93.
 66. Pettersson U, Nordstrom P, Lorentzon R. A comparison of bone mineral density and muscle strength in young male adults with different exercise level. *Calcif Tissue Int*. 1999 Jun;64(6):490-8.
 67. Szulc P, Beck TJ, Marchand F, Delmas PD. Low skeletal muscle mass is associated with poor structural parameters of bone and impaired balance in elderly men--the MINOS study. *J Bone Miner Res*. 2005 May;20(5):721-9.
 68. Gentil P, Lima RM, Jaco de Oliveira R, Pereira RW, Reis VM. Association between femoral neck bone mineral density and lower limb fat-free mass in postmenopausal women. *J Clin Densitom*. 2007 Apr-Jun;10(2):174-8.
 69. Gutin B, Kasper MJ. Can vigorous exercise play a role in osteoporosis prevention? A review. *Osteoporos Int*. 1992 Mar;2(2):55-69.
 70. Buchner DM, Larson EB. Falls and fractures in patients with Alzheimer-type dementia. *JAMA*. 1987 Mar 20;257(11):1492-5.
 71. Morris JC, Rubin EH, Morris EJ, Mandel SA. Senile dementia of the Alzheimer's type: an important risk factor for serious falls. *J Gerontol*. 1987 Jul;42(4):412-7.
 72. Oleske DM, Wilson RS, Bernard BA, Evans DA, Terman EW. Epidemiology of injury in people with Alzheimer's disease. *J Am Geriatr Soc*. 1995 Jul;43(7):741-6.
 73. Melton LJ 3rd, Beard CM, Kokmen E, Atkinson EJ, O'Fallon WM. Fracture risk in patients with Alzheimer's disease. *J Am Geriatr Soc*. 1994 Jun;42(6):614-9.
 74. Wang L, Larson EB, Bowen JD, van Belle G. Performance-based physical function and future dementia in older people. *Arch Intern Med*. 2006 May 22;166(10):1115-20.
 75. Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P, Kukull W. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. *Ann Intern Med*. 2006 Jan 17;144(2):73-81.
 76. Fitzpatrick AL, Buchanan CK, Nahin RL, Dekosky ST, Atkinson HH, Carlson MC, Williamson JD; Ginkgo Evaluation of Memory (GEM) Study investigators. Association of gait speed and other measures of physical function with cognition in a healthy cohort of elderly persons. *J Gerontol A Biol Sci Med Sci*. 2007 Nov;62(11):1244-51.
 77. Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. *J Gerontol A Biol Sci Med Sci*. 2002 Dec;57(12):M772-7.
 78. Szulc P, Duboeuf F, Marchand F, Delmas PD. Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study. *Am J Clin Nutr*. 2004 Aug;80(2):496-503.
 79. Leifke E, Korner HC, Link TM, Behre HM, Peters PE, Nieschlag E. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. *Eur J Endocrinol*. 1998 Jan;138(1):51-8.
 80. Boot AM, Engels MA, Boerma GJ, Krenning EP, De Muinck Keizer-Schrama SM. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. *J Clin Endocrinol*





THE JOURNAL OF NUTRITION, HEALTH & AGING®

- Metab. 1997 Aug;82(8):2423-8.
81. ter Maaten JC, de Boer H, Kamp O, Stuurman L, van der Veen EA. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. *J Clin Endocrinol Metab.* 1999 Jul;84(7):2373-80.
 82. Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, Wilson PW, Kiel DP. Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study. *J Clin Endocrinol Metab.* 1998 Dec;83(12):4257-62.
 83. Schedlich LJ, Muthukaruppan A, O'Han MK, Baxter RC. Insulin-like growth factor binding protein-5 interacts with the vitamin D receptor and modulates the vitamin D response in osteoblasts. *Mol Endocrinol.* 2007 Oct;21(10):2378-90.
 84. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE. Effects of human growth hormone in men over 60 years old. *N Engl J Med.* 1990 Jul 5;323(1):1-6.
 85. Thompson JL, Butterfield GE, Marcus R, et al. The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. *J Clin Endocrinol Metab.* 1995; 80:1845-1852.
 86. Yarasheski KE, Zachwieja JJ, Campbell JA, Bier DM. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. *Am J Physiol Endocrinol Metab.* 1995; 268:E268-76.
 87. Papadakis MA, Grady D, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. *Ann Intern Med.* 1996; 124:708-716.
 88. Lange KH, Isaksson F, Rasmussen MH, et al. GH administration and discontinuation in healthy elderly men: effects on body composition, GH-related serum markers, resting heart rate and resting oxygen uptake. *Clin Endocrinol.* 2001; 55:77-86.
 89. Blackman MR, Sorkin JD, Munzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. *JAMA.* 2002; 288:2282-2292.
 90. Cannon JG. Cytokines in aging and muscle homeostasis. *J Gerontol A Biol Sci Med Sci.* 1995 Nov;50 Spec No:120-3.
 91. Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, Penninx B, Pahor M, Wallace R, Havlik RJ. Serum IL-6 level and the development of disability in older persons. *J Am Geriatr Soc.* 1999 Jun;47(6):639-46.
 92. Bischoff-Ferrari HA, Orav EJ, Dawson-Hughes B. Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. *Arch Intern Med.* 2006 Feb 27;166(4):424-30.
 93. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA.* 2005 May 11;293(18):2257-64.
 94. Ooms ME, Vlasman P, Lips P, Nauta J, Bouter LM, Valkenburg HA. The incidence of hip fractures in independent and institutionalized elderly people. *Osteoporos Int.* 1994 Jan;4(1):6-10.
 95. Duque G, Mallet L, Roberts A, Gingrass S, Kremer R, Sainte-Marie LG, Kiel DP; Quebec Symposium for the Treatment of Osteoporosis in Long-Term Care. To treat or not to treat, that is the question: proceedings of the Quebec Symposium for the Treatment of Osteoporosis in Long-term Care Institutions, Saint-Hyacinthe, Quebec, November 5, 2004. *J Am Med Dir Assoc.* 2006 Sep;7(7):435-41.
 96. Papaioannou A, Kennedy CC, Ioannidis G, Gao Y, Sawka AM, Goltzman D, Tenenhouse A, Pickard L, Olszynski WP, Davison KS, Kaiser S, Josse RG, Kreiger N, Hanley DA, Prior JC, Brown JP, Anastassiades T, Adachi JD; CaMos Research Group. The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. *Osteoporos Int.* 2007 Oct 9
 97. Kamel HK. Underutilization of calcium and vitamin D supplements in an academic long-term care facility. *J Am Med Dir Assoc.* 2004 Mar-Apr;5(2):98-100.
 98. Saliba D, Solomon D, Rubenstein L, Young R, Schnelle J, Roth C, Wenger N. Quality indicators for the management of medical conditions in nursing home residents. *J Am Med Dir Assoc.* 2005 May-Jun;6(3 Suppl):S36-48.
 99. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. *Osteoporos Int.* 2004 Oct;15(10):767-78.
 100. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. *Osteoporos Int.* 2004 Dec;15(12):1003-8.
 101. Johansen A, Evans W, Stone M. Bone assessment in elderly women: what does a low bone ultrasound result tell us about bone mineral density? *Arch Gerontol Geriatr.* 1999 May-Jun;28(3):239-46.
 102. McLean RR, Hannan MT, Epstein BE, Bouxsein ML, Cupples LA, Murabito J, Kiel DP. Elderly cohort study subjects unable to return for follow-up have lower bone mass than those who can return. *Am J Epidemiol.* 2000 Apr 1;151(7):689-92.
 103. Lips P, Ooms ME. Non-pharmacological interventions. *Baillieres Best Pract Res Clin Endocrinol Metab.* 2000 Jun;14(2):265-77.
 104. Haapasalo H, Kontulainen S, Sievanen H, Kannus P, Jarvinen M, Vuori I. Exercise-induced bone gain is due to enlargement in bone size without a change in volumetric bone density: a peripheral quantitative computed tomography study of the upper arms of male tennis players. *Bone.* 2000 Sep;27(3):351-7.
 105. Lynch NA, Ryan AS, Evans J, Katzell LI, Goldberg AP. Older elite football players have reduced cardiac and osteoporosis risk factors. *Med Sci Sports Exerc.* 2007 Jul;39(7):1124-30.
 106. Klein CS, Allman BL, Marsh GD, Rice CL. Muscle size, strength, and bone geometry in the upper limbs of young and old men. *J Gerontol A Biol Sci Med Sci.* 2002 Jul;57(7):M455-9.
 107. Judex S, Gross TS, Zernicke RF. Strain gradients correlate with sites of exercise-induced bone-forming surfaces in the adult skeleton. *J Bone Miner Res.* 1997 Oct;12(10):1737-45.
 108. Hsieh YF, Robling AG, Ambrosius WT, Burr DB, Turner CH. Mechanical loading of diaphyseal bone in vivo: the strain threshold for an osteogenic response varies with location. *J Bone Miner Res.* 2001 Dec;16(12):2291-7.
 109. Nelson ME, Fiatarone MA, Morganti CM, Trice I, Greenberg RA, Evans WJ. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trial. *JAMA.* 1994 Dec 28;272(24):1909-14.
 110. Vincent KR, Braith RW. Resistance exercise and bone turnover in elderly men and women. *Med Sci Sports Exerc.* 2002 Jan;34(1):17-23.
 111. Basseij EF, Rothwell MC, Littlewood JJ, Pye DW. Pre- and postmenopausal women have different bone mineral density responses to the same high-impact exercise. *J Bone Miner Res.* 1998 Dec;13(12):1805-13.
 112. Villareal DT, Steger-May K, Schechtman KB, Yarasheski KE, Brown M, Sinacore DR, Binder EF. Effects of exercise training on bone mineral density in frail older women and men: a randomised controlled trial. *Age Ageing.* 2004 May;33(3):309-12.
 113. Frost HM. Skeletal structural adaptations to mechanical usage (SATMU): 4. Mechanical influences on intact fibrous tissues. *Anat Rec.* 1990 Apr;226(4):433-9.
 114. Villareal DT, Binder EF, Yarasheski KE, Williams DB, Brown M, Sinacore DR, Kohrt WM. Effects of exercise training added to ongoing hormone replacement therapy on bone mineral density in frail elderly women. *J Am Geriatr Soc.* 2003 Jul;51(7):985-90.
 115. Judge JO, Lindsey C, Underwood M, Winsemius D. Balance improvements in older women: effects of exercise training. *Phys Ther.* 1993;73:254-65.
 116. Wolf SL, Barnhart HX, Kutner NG, et al. Reducing frailty and falls in older persons: an investigation of Tai Chi and computerized balance training. *J Am Geriatr Soc.* 1996;44:489-97.
 117. Sattin RW, Easley KA, Wolf SL, Chen Y, Kutner MH. Reduction in fear of falling through intense tai chi exercise training in older, transitionally frail adults. *J Am Geriatr Soc.* 2005 Jul;53(7):1168-78.
 118. Wickham C, Walsh K, Cooper C, et al. Dietary calcium, physical activity, and risk of hip fracture: a prospective study. *BMJ.* 1989;299:889-92.
 119. Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. *N Engl J Med.* 1994;331:821-7.
 120. Fiatarone MA, O'Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. *N Engl J Med.* 1994;330:1769-75.
 121. Rubenstein LZ, Josephson KR, Trueblood PR, Loy S, Harker JO, Pietruszka FM, Robbins AS. Effects of a group exercise program on strength, mobility, and falls among fall-prone elderly men. *J Gerontol A Biol Sci Med Sci.* 2000 Jun;55(6):M317-21.
 122. Bonnefoy M, Cornu C, Normand S, Boutitie F, Bugnard F, Rahmani A, Lacour JR, Laville M. The effects of exercise and protein-energy supplements on body composition and muscle function in frail elderly individuals: a long-term controlled randomised study. *Br J Nutr.* 2003;89:731-9.
 122. Volpi E, Sheffield-Moore M, Rasmussen BB, Wolfe RR. Basal muscle amino-acid kinetics and protein synthesis in healthy young and older men. *JAMA.* 2001; 286:1206-1212.
 123. Morais JA, Chevalier S, Gougeon R. Protein turnover and requirements in the healthy and frail elderly. *J Nutr Healthy Aging.* 2006 Jul-Aug;10(4):272-83.
 124. Borst SE. Intervention for sarcopenia and muscle weakness in older people. *Age Ageing.* 2004;33:548-555.
 125. Cederholm T, Hedstrom M. Nutritional treatment of bone fracture. *Curr Opin Clin Nutr Metab Care.* 2005 Jul;8(4):377-81.
 126. Oliver D, Connelly JB, Victor CR, Shaw FE, Whitehead A, Gene Y, Vanoli A, Martin FC, Gosney MA. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. *BMJ.* 2007 Jan 13;334(7584):82.
 127. Parker MJ, Gillespie WJ, Gillespie LD. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. *BMJ.* 2006 Mar 11;332(7541):571-4.
 128. Kiel DP, Magaziner J, Zimmerman S, Ball L, Barton BA, Brown KM, Stone JP, Dewkett D, Birge SJ. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. *JAMA.* 2007 Jul 25;298(4):413-22.
 129. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ. Prevalence of vitamin D insufficiency in an adult normal population. *Osteoporos Int.* 1997;7(5):439-43.
 130. Vecino-Vecino C, Gratton M, Kremer R, Rodriguez-Manas L, Duque G. Seasonal





FRAILITY, OSTEOPOROSIS AND HIP FRACTURE

- variance in serum levels of vitamin d determines a compensatory response by parathyroid hormone: study in an ambulatory elderly population in Quebec. *Gerontology*. 2006;52(1):33-9.
131. Fardellone P, Brazier M, Kamel S, Guéris J, Graulet AM, Liénart J, Sebert JL. Biochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake. *Am J Clin Nutr*. 1998;67:1273-8.
 132. Parfitt AM, Gallagher JC, Heaney RP, Johnston CC, Neer R, Whedon GD. Vitamin D and bone health in the elderly. *Am J Clin Nutr*. 1982; 36, 1014-31.
 133. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ. Vitamin D3 and calcium to prevent hip fractures in the elderly women. *N Engl J Med*. 1992 Dec 3;327(23):1637-42.
 134. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, Anderson FH, Cooper C, Francis RM, Donaldson C, Gillespie WJ, Robinson CM, Torgerson DJ, Wallace WA; RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. *Lancet*. 2005 May 7-13;365(9471):1621-8.
 135. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O'Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D; Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. *N Engl J Med*. 2006 Feb 16;354(7):669-83.
 136. Boirie Y, Gachon P, Beaufre B. Splanchnic and whole-body leucine kinetics in young and elderly men. *Am J Clin Nutr*. 1997; 65:489-95.
 137. Volpi E, Ferrando AA, Yeckel CW, et al. Exogenous amino-acids stimulate net muscle protein synthesis in the elderly. *J Clin Invest* 1998; 101:2000-7.
 138. Volpi E, Mittendorfer B, Wolf SE, Wolfe RR. Oral amino acids stimulate muscle protein anabolism in the elderly despite higher first-pass splanchnic extraction. *Am J Physiol* 1999; 277:E513-20.
 139. Visser M, Deeg DJ, Lips P; Longitudinal Aging Study Amsterdam. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. *J Clin Endocrinol Metab*. 2003 Dec;88(12):5766-72.
 140. Rolland YM, Perry HM 3rd, Patrick P, Banks WA, Morley JE. Loss of appendicular muscle mass and loss of muscle strength in young postmenopausal women. *J Gerontol A Biol Sci Med Sci*. 2007 Mar;62(3):330-5.
 141. Stein MS, Wark JD, Scherer S, Walton SL, Chick P, Carantonio MD, Zajac JD, Flicker L. Falls relate to vitamin D and parathyroid hormone in an Australian nursing home and hostel. *J Am Geriatr Soc*. 1999;47:1195-1201.
 142. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. *Endocr Rev*. 2005 Aug;26(5):688-703.
 143. Gerdhem P, Ringsberg KA, Obrant KJ, Akesson K. Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. *Osteoporos Int*. 2005 Nov;16(11):1425-31.
 144. Greenspan SL, Schneider DL, McClung MR, Miller PD, Schnitzer TJ, Bonin R, Smith ME, DeLuca P, Gormley GJ, Melton ME. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 2002 May 21;136(10):742-6.
 145. Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J, Kaufman JM, Hoszowski K, Varela AR, Fiore C, Brixen K, Reginster JY, Boonen S. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. *J Bone Miner Res*. 2006 Jul;21(7):1113-20.
 146. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA*. 2002 Jul 17;288(3):321-33.
 147. Villareal DT, Binder EF, Williams DB, Schechtman KB, Yarasheski KE, Kohrt WM. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. *JAMA*. 2001 Aug 15;286(7):815-20.
 148. Kohrt WM, Snead DB, Slatopolsky E, Birge SJ Jr. Additive effects of weight-bearing exercise and estrogen on bone mineral density in older women. *J Bone Miner Res*. 1995 Sep;10(9):1303-11.
 149. Jacobsen DE, Samson MM, Kezic S, Verhaar HJJ. Postmenopausal HRT and tibolone in relation to muscle strength and body composition. *Maturitas*. 2007;58(1):7-18.
 150. Lemoine S, Granier P, Tiffoche C, Rannou-Bekono F, Thieulant ML, Delamarch P. Estrogen receptor alpha mRNA in human skeletal muscles. *Med Sci Sports Exerc* 2003;35:439-43.
 151. Wiik A, Ekman M, Morgan G, Johansson O, Jansson E, Esbjörnsson M. Oestrogen receptor beta is present in both muscle fibres and endothelial cells within human skeletal muscle tissue. *Histochem Cell Biol* 2005;124:161-5.
 152. Hansdotter H, Franzon L, Prestwood K, Sigurdsson G. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. *J Am Geriatr Soc*. 2004 May;52(5):779-83.
 153. Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. *Metabolism*. 1997 Apr;46(4):410-3.
 154. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. *N Engl J Med*. 1996; 335: 1-7.
 155. Percheron G, Hogrel JY, Denot-Ledunois S, Fayet G, Forette F, Baulieu EE, Fardeau M, Marini JF; Double-blind placebo-controlled trial. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. *Arch Intern Med*. 2003 Mar 24;163(6):720-7.
 156. Ross R, Miell J, Freeman E, Jones J, Matthews D, Preece M, Buchanan C. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. *Clin Endocrinol (Oxf)*. 1991 Jul;35(1):47-54.
 157. Yeo AL, Levy D, Martin FC, Sonksen P, Sturgess I, Wheeler MM, Young A. Frailty and the biochemical effects of recombinant human growth hormone in women after surgery for hip fracture. *Growth Horm IGF Res*. 2003 Dec;13(6):361-70.
 158. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. *Endocr Rev*. 1993 Feb;14(1):20-39.
 159. Takala J, Ruokonen E, Webster NR. Increased mortality associated with growth hormone treatment in critically ill adults. *N Engl J Med* 1999;341:785
 160. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. *JAMA*. 2001 Feb 14;285(6):785-95.
 161. Cawthon PM, Marshall LM, Michael Y, Dam TT, Ensrud KE, Barrett-Connor E, Orwoll ES; Osteoporotic Fractures in Men Research Group. Frailty in older men: prevalence, progression, and relationship with mortality. *J Am Geriatr Soc*. 2007 Aug;55(8):1216-23.
 162. Purser JL, Kuchibhatla MN, Fillenbaum GG, Harding T, Peterson ED, Alexander KP. Identifying frailty in hospitalized older adults with significant coronary artery disease. *J Am Geriatr Soc*. 2006 Nov;54(11):1674-81.
 163. Ble A, Cherubini A, Volpato S, Bartali B, Walston JD, Windham BG, Bandinelli S, Lauretani F, Guralnik JM, Ferrucci L. Lower plasma vitamin E levels are associated with the frailty syndrome: the InCHIANTI study. *J Gerontol Bio Sci Med Sci* 2006;61A:278-283.
 164. Woods NF, LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Brunner RL, Masaki K, Murray A, Newman AB. Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. *J Am Geriatr Soc* 2005;53:1321-1330.
 165. Ottenbacher KJ, Ostir GV, Peek MK, Snih SA, Raji MA, Markides KS. Frailty in older Mexican Americans. *J Am Geriatr Soc* 2005;53(9):1524-1531.
 166. Rockwood K, Howlett SE, MacKnight C, Beattie BL, Bergman H, Hébert R, Hogan DB, Wolfson C, McDowell I. Prevalence, attributes, and outcomes of fitness and frailty in community-dwelling older adults: report from the Canadian study of health and aging. *J Gerontol A Biol Sci Med Sci*. 2004 Dec;59(12):1310-7.
 167. Nourhashemi F, Andrieu S, Gillette-Guyonnet S, Vellas B, Albaredo JL, Grandjean H. Instrumental activities of daily living as a potential marker of frailty: a study of 7364 community-dwelling elderly women (the EPIDOS study). *J Gerontol A Biol Sci Med Sci*. 2001 Jul;56(7):M448-53.

